Skip to main content

Table 1 Characteristics of the studied populations

From: Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma

 

Patients with ALL

Patients with OSC

Total

Number of patients

622

39

661

Gender n (%)

 Male

372 (60)

27 (69)

399 (60)

 Female

250 (40)

12 (31)

262 (40)

Age at diagnosis (%)

  < 1 yr. n

7 (1)

0

7 (1)

 1–10 yr. n

505 (81)

9 (23)

515 (78)

  > 10 yr. n

109 (18)

30 (77)

138 (21)

 Mean ± SD yr

6.39 (±4.3)

13.1 (±3.5)

6.6 (±4.3)

 Median (range) yr

5.2 (0–18)

13.2 (5–18)

5.3 (0–18)

Risk group n (%)

 SR

165 (27)

3 (7)

168 (25)

 IR

355 (57)

24 (62)

379 (58)

 HR

100 (16)

12 (31)

112 (17)

Chemotherapy protocol n (%)

 Protocols before 20001

325 (52)

325 (52)

 Protocols after 20002

297 (48)

297 (48)

 OSC protocols

39

39

Anthracycline dose3 (range, mg/m2)

60–840

180–360

60–840

Anthracycline dose n (%)

  ≤ 240 mg/m2

457 (74)

6 (15)

463 (70)

  > 240 mg/m2

163 (26)

33 (85)

196 (30)

Patients with pathological FS4 n

18

2

20

  1. Data are reported as numbers with percentages, unless mentioned otherwise. Abbreviations: ALL, acute lymphoid leukemia; OSC, osteosarcoma; SD, standard deviation; SR, standard-risk; IR, intermediate-risk; HR, high-risk; FS, left ventricular fractional shortening. 1ALL patients treated with ALL BFM 88, ALL BFM 90, ALL BFM 95, Interfant 98, NHL BFM 90 or NHL BFM 95 protocol. 2ALL patients treated with ALL IC BFM 2002, ALL IC BFM 2009 or Interfant 2006 protocol. 3Cumulative anthracycline dose in doxorubicin or daunorubicin equivalent doses during the treatment according to protocol. 4FS below 28%